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Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are currently recognized as themost common genetic cause of parkinsonism.
Among the large number of LRRK2 mutations identified to date, the G2019S variant is the most common. In Asia, however, another
LRRK2 variant, G2385R, appears to occur more frequently. To better understand the contribution of different LRRK2 variants toward
disease pathogenesis, we generated transgenic Drosophila over-expressing various human LRRK2 alleles, including wild type, G2019S,
Y1699C, and G2385R LRRK2.We found that transgenic flies harboring G2019S, Y1699C, or G2385R LRRK2 variant, but not the wild-type
protein, exhibit late-onset loss of dopaminergic (DA) neurons in selected clusters that is accompanied by locomotion deficits. Further-
more, LRRK2 mutant flies also display reduced lifespan and increased sensitivity to rotenone, a mitochondrial complex I inhibitor.
Importantly, coexpression of human parkin in LRRK2 G2019S-expressing flies provides significant protection against DA neurodegen-
eration that occurs with age or in response to rotenone. Together, our results suggest a potential link between LRRK2, parkin, and
mitochondria in the pathogenesis of LRRK2-related parkinsonism.
Introduction
Parkinson disease (PD) is a prevalent neurodegenerative move-
ment disorder characterized pathologically by the rather selective
loss of dopaminergic (DA) neurons in the substantia nigra pars
compacta. Although most cases of PD occur in a sporadic man-
ner, a subset of PD cases is inheritable and attributable to muta-
tions in specific genes, which include -synuclein, parkin, DJ-1,
PINK1, and LRRK2 (Thomas and Beal, 2007; Gupta et al., 2008).
Of these, LRRK2mutations are currently recognized as the most
common genetic cause of parkinsonism (Paisa´n-Ruíz et al., 2004;
Zimprich et al., 2004). To date, a large number of LRRK2 muta-
tions have been identified. Among these, the G2019S variant is
themost common, with frequencies reaching up to 40% inNorth
African PD populations (Lesage et al., 2006). In Asia, however,
another LRRK2 variant, i.e., G2385R, appears to occur more fre-
quently (Tan and Schapira, 2008).
Structurally, LRRK2 is a large protein (2527 aa) comprised of
multiple domains, including a GTPase domain and a kinase do-
main capable of exhibiting a GTP-dependent phosphorylation
activity (West et al., 2005). In general, disease-associated muta-
tions of LRRK2 tend to increase its kinase activity and thereby its
toxicity (Smith et al., 2006; West et al., 2007). However, signifi-
cant variations do occur. For example, the I2012TLRRK2mutant
appears to have reduced kinase activity (West et al., 2007), and
several LRRK2 mutants also exhibit a propensity to aggregate
when expressed in cultured cells (Greggio et al., 2006). Thus, the
exactmechanism bywhich LRRK2mutations cause disease is not
entirely clear.
To understand the contribution of LRRK2 mutations in vivo,
a number of groups have recently generatedDrosophilamodels of
LRRK2mutant-induced parkinsonism. Notably, Liu et al. (2008)
found that over-expression of human wide-type LRRK2 or the
G2019S mutant in flies triggers marked degeneration in their pho-
toreceptor cells and DA neurons in general. Similarly, Imai et al.
(2008) observed neurodegeneration in flies expressing Drosophila
orthologs of human LRRK2 Y1699C or I2020T mutants, although
the degeneration in this case was confined to certain DA neuronal
clusters and does not affect the eye. In contrast, Lee et al. (2007)
reported that transgenic flies over-expressing orthologous human
wild type or R1441C mutant LRRK2 do not exhibit any significant
defects in the tissues examined, includingDAneurons andmuscles.
Here, we report that transgenic Drosophila over-expressing
human LRRK2G2019S, Y1699C, or theG2385R variants, but not
the wild-type protein, exhibit late-onset loss of DA neurons in
selected clusters that are accompanied by locomotion deficits.
Furthermore, LRRK2mutant flies, especially those expressing the
G2019S variant, also display increased sensitivity to rotenone, a
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mitochondrial complex I inhibitor. Importantly, coexpression of
humanparkin in LRRK2G2019S-expressing flies provides signif-
icant protection against DA neurodegeneration that occurs with
age or in response to rotenone. Together, our results demonstrate
that disease-associated LRRK2 variants promote DA neuronal
degeneration in vivo and that parkin over-expression mitigates
LRRK2-induced neurotoxicity.
Materials andMethods
Fly stocks. Fly lines for elav-Gal4, dopa decarboxylase gene (ddc)–Gal4,
and glass multiple reporter (GMR)--Gal4 were obtained from the Bloom-
ington Stock Center. Human parkin-expressing flies were described pre-
viously (Wang et al., 2007). To generate transgenic human LRRK2 flies,
human wild type or mutant LRRK2 (Y1699C, G2019S, and G2385R)
cDNA containing a myc-tag at the C terminus (West et al., 2007) was
inserted into pUAST plasmid and microinjected into Drosophila em-
bryos (BestGene). Sequencing of cloned products was performed before
they were microinjected into the embryos.
Immunohistochemistry and scanning electron microscopy. Immunohis-
tochemical analysis of whole-mount adult fly brains were prepared ac-
cording to published protocols (Whitworth et al., 2005; Wang et al.,
2007) and stained with rabbit anti-tyrosine hydroxylase (anti-TH) (1:
200; Pel-Freez Biologicals), rat anti-elav (1:10; Developmental Studies
Hybridoma Bank), or rabbit anti-LRRK2 (1:100; Novus Biologicals) as
primary antibodies before visualization using confocal microscopy. We
analyzed DA neurons in different clusters quantitatively according to the
method described by Whitworth et al. (2005). To analyze the morphol-
ogy of eyes in high definition, fly heads were dissected at day 20 or day 60
after eclosion, mounted, and visualized using the scanning electron mi-
croscope Jeol JSM-6300LV.
Climbing assays and rotenone treatment. Climbing assays were per-
formed according to the method described previously (Wang et al.,
2007). Three groups of 20 female adult flies that express the transgenes
under the direction of theDdc–GAL4driverwere anesthetized andplaced
in a vertical plastic column (length, 25 cm; diameter, 1.5 cm). Age-
matched normal flies were used as controls. After a 2 h recovery period
fromCO2 exposure, flieswere gently tapped to the bottomof the column.
The number of flies that reached the top of column at 1 min was then
counted. Three trials were performed in each experiment at 15 min in-
tervals. The scores represent themean percentage of flies that reached the
top against the total number tested. Results are presented as mean 
SEM of the scores obtained in three independent experiments. In
rotenone-treated flies, flies were fed with cornmeal-agar medium con-
taining 50M rotenone (Sigma) immediately at after eclosion and during
the entire experimental period. This concentration of rotenone is 5–10-
fold lower than that originally reported by Coulom and Birman (2004).
Statistical analysis. Quantitative data are expressed as mean  SEM,
unless otherwise stated. Statistical significance for all the quantitative
data obtained was analyzed using the Student’s t test (*p  0.05, **p 
0.001), unless otherwise stated.
Results
Transgenic LRRK2-expressing flies do not display obvious
eye abnormalities
To examine the effects of LRRK2 mutant expression in vivo, we
generated transgenic Drosophila expressing myc-tagged human
Figure 1. Expression of LRRK2 transgenes in Drosophila neither affects its overall brain architecture nor triggers obvious eye abnormalities. A, Left, Anti-elav (green) and anti-LRRK2 (red)
immunostaining of whole-mount adult brains derived from 2-d-old control or transgenic flies expressing wild-type human LRRK2, as indicated. Right, Enlarged images (and inset) show the
localization of elav and LRRK2 signals to the nucleus and cytoplasm, respectively, in the brain of a wild-type LRRK2-expressing fly. An anti-myc immunoblot of brain lysates prepared from 2-d-old
control or transgenic flies expressing various LRRK2 species is shown below (genotype: elav-Gal4/ or elav–Gal4–hLRRK2). B, SEM eye images of 20-d-old GMR-Gal4/ or GMR–Gal4–hLRRK
adult flies. No retinal degeneration was observed in all flies examined.
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LRRK2G2019S, Y1699C, orG2385R species under the regulation
of the GAL4/upstream activation sequence system, which allows
tissue-specific expression of transgenes (Fig. 1A). As a control, we
also generated Drosophila producing myc-tagged wild-type hu-
man LRRK2. When driven by the pan-neuronal embryonic lethal
abnormal vision (elav)–GAL4driver, the expression of the various
transgenic LRRK2 species in the fly’s neurons is robust and local-
ized predominantly to the cytoplasm (Fig. 1A; supplemental Fig.
S1A, available at www.jneurosci.org as supplemental material).
Notably, the staining pattern of LRRK2 is rather punctuate, likely
a reflection of its localization tomembranous and vesicular struc-
tures, as reported previously (Biskup et al., 2006). Although
LRRK2-expressing cells are devoid of classical Lewy body-like inclu-
sion bodies,mutant LRRK2 species tend to form intracellular aggre-
gates (supplemental Fig. S1A, available at www.jneurosci.org as
supplemental material). Consistent with previous reports (Imai et
al., 2008;Liuet al., 2008),we foundthatneitherwild typenormutant
LRRK2 expression appears to compromise the overall anatomical
integrity of the fly’s brain up to 60 d after eclosion (Fig. 1A) (data
not shown for LRRK2 variants), suggesting the LRRK2-induced
toxicity, if any, is specific to selected populations of neuronal
cells. In view of the conflicting observations regarding the effects
on LRRK2 expression on eye maintenance in flies (Imai et al.,
2008; Liu et al., 2008), we next expressed the various LRRK2
species in an eye-specific manner via the GMR–GAL4 promoter.
Scanning electron microscope analysis reveals no apparent eye
abnormalities in these flies at 20 d after eclosion expressing either
wild-type or mutant LRRK2 species (Fig. 1B). Similar observa-
tions were made when these flies were aged to 60 d; although a
very small percentage (1%) of GMR–GAL4-driven, G2019S-
expressing 60-d-old flies do exhibit a rough eye phenotype
(supplemental Fig. S1B, available at www.jneurosci.org as sup-
plemental material), which is likely attributable to spontaneous
mutational events.
LRRK2mutant expression driven by ddc–GAL4 in flies
promotes DA neurodegeneration, locomotion deficits,
andmortality
To examine the effects of transgenic LRRK2 expression in DA
neurons, we used a driver line containing the promoter for the
ddc gene (ddc–GAL4) that drives transgene expression specifi-
cally in TH-positive neurons, as described previously (Wang et
al., 2007). At least six DA neuronal clusters [protocerebral ante-
rior lateral (PAL), PPM1, PPM2, PPM3, PPL1, and PPL2] are
recognizable in each of the adult fly brain hemispheres, all of
which are amenable to quantitative analysis (Lim and Ng, 2009).
At 1 d or 20 d after eclosion, none of the ddc–GAL4-driven
LRRK2-expressing flies register appreciable loss ofDAneurons in
any of these clusters (Fig. 2A; supplemental Fig. S2A, available at
www.jneurosci.org as supplemental material). However, in aged
flies (60 d old) expressing the pathogenic G2019S and Y1699C
LRRK2 mutants, we observed significant degeneration of DA
neurons in the PPM clusters 1 and 3 compared with age-matched
normal control flies (Fig. 2B,C). This terminal age-linked phe-
nomenon is consistent with the late disease-onset of LRRK2-
related parkinsonism. Interestingly, flies expressing the G2385R
variant also display similar, age-dependent, pattern of degeneration
as the G2019S LRRK2-expressing flies (Fig. 2B,C). In contrast, all
theDAneuronal clusters, includingPPM1and3, remainunaffected
inwild-type LRRK2-expressing flies relative to age-matched control
flies (Fig. 2B,C).
Notably, we and others have demonstrated a direct association
betweenDAneurodegenerationand locomotion impairment in flies
expressing disease-associated PD-linked proteins (Sang et al., 2007;
Figure 2. Expression of LRRK2mutants in flies promotes DA neurodegeneration and concomitant locomotion deficits.A,B, Bar graph showing the number of TH-positive DA neurons in different
clusters of various fly species at 20 or 60 d after eclosion, as indicated (n 10). C, Representative confocal microscopy images showing TH-positive (red) DA neurons in the PPM1 cluster (boxed) of
60-d-old control or LRRK2-expressing flies. Inset, Higher magnification of boxed regions. D, E, Bar graph showing the percentage of various male (D) and female (E) flies at different days after
eclosion that reached the top of assay column after 1 min (n 20) (genotype: ddc–Gal4/ or ddc–Gal4–hLRRK2).
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Wang et al., 2007). To examine whether
such a relationship exists in aged LRRK2-
expressing flies that exhibit a significant loss
of DA neurons, we tested the climbing abil-
ity of the various transgenic flies at 60 d after
eclosion. Correlating with the significant
loss of DA neurons, we found that aged
flies expressing either G2019S or Y1699C
LRRK2, but not the wild-type protein, re-
corded dramatically poorer climbing scores
(10% success) compared with control
flies, aphenomenon that appears tobe inde-
pendent of gender (Fig. 2D,E). Although
G2385RLRRK2-expressing flies at 60dafter
eclosion display apparent DA neurodegen-
eration, unexpectedly their climbing ability
is not significantly compromised (Fig.
2D,E). It is possible thatG2019S orY1699C
LRRK2mutant expressionmayadditionally
affect the function of surviving DA neurons
thatotherwise could compensate for the lost
neurons. For example, G2019S or Y1699C
expression could alter the level of dopa-
mine production. Supporting this, we
found that L-DOPA administration mark-
edly improves the climbing ability of aged
G2019S- and Y1699C LRRK2-expressing
flies (supplemental Fig. S2B, available at
www.jneurosci.org as supplemental mate-
rial). Furthermore, HPLC analysis revealed
that the level of dopamine in G2019S
LRRK2-expressing flies is significantly re-
duced compared with wild-type LRRK2-
expressing flies (supplemental Fig. S2B,
available at www.jneurosci.org as supple-
mental material). Finally, during the course
of our examination, we noticed that the viability of the various
LRRK2 mutant-expressing flies differs significantly from control
flies or those expressingwild-typeLRRK2.We found that expression
of G2019S; Y1699C and G2385R variants in DA neurons reduced
their lifespan, with G2019S LRRK2-expressing flies showing the
highest rate of mortality (supplemental Fig. S2C, available at www.
jneurosci.org as supplemental material).
Rotenone treatment aggravates LRRK2mutant-induced
DA neurodegeneration
Next, we challenged the various transgenic LRRK2-expressing flies
with rotenone to examine the relative susceptibility of theirDAneu-
rons to degeneration in response to a PD-linked environmental
toxin. We found an accelerated loss of DA neurons in the PPM 2/3
clusters of rotenone-treated flies expressing either G2019S or
G2385RLRRK2alleles that are beyond that occurring in control flies
or corresponding untreated flies (Fig. 3A,B). This phenomenon is
not observedwhenLRRK2-expressing flieswere treatedwith vehicle
(DMSO) alone (supplemental Fig. S2D, available at www.jneurosci.
org as supplemental material). Interestingly, markedly accelerated
DAneuronal degeneration in the PAL cluster also occurs inG2385R
LRRK2-expressing flies (Fig. 3A,B). In contrast, the rate ofDAneu-
rodegeneration in flies expressingwild-type LRRK2 is not enhanced
by rotenone treatment relative to control flies (Fig. 3A,B). Surpris-
ingly, rotenone treatment fails to aggravate the phenotype of
Y1699C LRRK2-expressing flies at the end of the 15 d experimental
period. Our results thus suggest that both G2019S- and G2385R
LRRK2-expressing flies are more susceptible to rotenone-induced
DA neurodegeneration.
Parkin mitigates LRRK2 G2019Smutant-induced
DA degeneration
Wehave previously demonstrated that flies over-expressingwild-
type human parkin are significantly protected against rotenone-
induced DA neurodegeneration (Wang et al., 2007). To examine
whether parkin couldmitigate G2019S LRRK2-induced DA neu-
rodegeneration in Drosophila in the presence of rotenone, we
generated fly lines that coexpress parkin with either wild-type
(WT/PK) or G2019S LRRK2 (G2019S/PK) and repeated our
above study with these bigenic flies. Whereas the DA neuron
number in wild-type LRRK2-expressing flies remains essentially
unchanged in the presence or absence of parkin coexpression,
over-expressed parkin expectedly affords significant protection
against rotenone-induced acceleration of DA neurodegeneration
in LRRK2 G2019S-expressing flies (Fig. 4A,B). Since parkin
functions as a broad-spectrum neuroprotectant, we surmised
that G2019S/PK flies might also be protected against DA neuro-
nal degeneration promoted by age. Indeed, the PPM 1 and 3
clusters that otherwise registered a marked loss in aged G2019S
LRRK2-expressing flies relative to age-matched control flies are
now maintained in G2019S/PK flies at day 60 (Fig. 4C). Parkin
coexpression thus significantly mitigates DA neurodegeneration
induced by LRRK2 G2019S mutant in the presence or absence of
externally applied stress.
Figure 3. Exposure to rotenone accelerates DA degeneration in LRRK2 G2019 and G2385R mutant flies. A, Bar graph showing
the number of TH-positive DA neurons in different clusters of various fly species at 15 d after rotenone treatment (n 15). B,
Representative confocal microscopy images showing TH-positive (red) DA neurons in the PPM3 cluster of various, rotenone-
treated fly species, as indicated (genotype: ddc–Gal4/ or ddc–Gal4–hLRRK2).
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Discussion
Themajor finding of our present study conducted in theDrosophila
is that rotenone aggravates, whereas parkinmitigates, the otherwise
late-onset loss of DA neurons triggered by the expression of LRRK2
G2019S mutant. Furthermore, we also demonstrate that two other
LRRK2 variants, including G2385R, which is considered to be a risk
allele among Asian population, produce similar phenotypes as
LRRK2 G2019S mutant when expressed as transgenes in flies. Our
study suggests that although a significant length of time is normally
required for disease-associated LRRK2 mutants to manifest their
toxicity, the pathogenic process can be
hastened by an exogenous inhibitor ofmi-
tochondrial complex I, which implies
a gene–environment interaction. More-
over, parkin rescues both mutant LRRK2
and rotenone-enhanced DA neuronal cell
loss. This putative link between LRRK2,
parkin, and mitochondria has direct
mechanistic and therapeutic implications
for LRRK2-induced parkinsonism.
Consistent with the report by Imai et
al. (2008), we found that mutant LRRK2-
mediated degeneration occurs only to-
ward the terminal age of the fly and is
restricted to selected clusters of DA neu-
rons, whereas transgenic flies expressing
wild-type LRRK2 are spared from this
age-associated phenotype. This is unlike
parkin null flies, where significant DA de-
generation could be observed as early as
1 d after eclosion (Wang et al., 2007), a
phenotype consistent with the earlier on-
set of parkin-related disease. Notably, our
and other investigator’s (Lee et al., 2007;
Imai et al., 2008) findings are in stark con-
trast to the report by Liu et al. (2008)
where degeneration in Drosophila ex-
pressing either wild type or G2019S
LRRK2 was observed to occur nonselec-
tively across all the DA neuronal clusters.
Furthermore, Liu et al. (2008) also de-
tected significant retinal degeneration in
their transgenic LRRK2 flies at as early as 3
weeks of age after eclosion. This phenom-
enon is neither observed in our current
study with flies at 20 or 60 d after eclosion
nor in studies reported by other investiga-
tors (Lee et al., 2007; Imai et al., 2008).
The significant phenotypic variations be-
tween our LRRK2 and the other reported
models (Lee et al., 2007; Imai et al., 2008)
and the one generated by Liu et al. (2008)
may be attributable the different fly strains
used or the use of artificial constructs opti-
mized for protein expression (Smith et al.,
2006) in Liu et al. (2008).
To date, the exact mechanism by
which LRRK2mutations cause disease re-
mains elusive, but increased kinase activ-
ity of the protein is thought to be an
important contributor to its neurotoxicity
(West et al., 2005; Greggio et al., 2006;
Smith et al., 2006). That being the case,
elevating the expression ofwild-type LRRK2 expression should in
theory result in a mathematical increase in LRRK2-mediated ca-
talysis and thereby neurotoxicity in susceptible host cells. How-
ever, our results, as well as those from two related studies (Lee et
al., 2007; Imai et al., 2008), would suggest that a mere enhance-
ment of wild-type LRRK2 expression alone, either in the presence
or absence of rotenone, is not sufficient to phenocopy the effects
produced by LRRK2mutations in vivo. A tempting speculation is
that wild-type LRRK2 normally exists in an inactivated state in
vivo independent of its expression levels. However, this does not
Figure 4. Parkin coexpression mitigates DA degeneration in LRRK2 G2019S-expressing flies in the presence or absence of
rotenone. A, Bar graph showing the number of TH-positive DA neurons in different clusters of various fly species at 15 d after
rotenone treatment (n 15). B, Representative confocal microscopy images showing TH-positive (red) DA neurons in whole-
mount adult brains derived from rotenone-treated flies expressing either LRRK2 G2019S alone or in the presence of parkin
coexpression. Right, PPM3 cluster (circled) are shown at highermagnification. C, Bar graph showing the number of TH-positive DA
neurons in different clusters of the various fly species at 60 d after eclosion, as indicated (n 8) (genotype: ddc–Gal4/ or
ddc–Gal4–hLRRK2 or ddci-Gal4–hLRRK2;ddc–Gal4–hparkin).
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adequately explain the phenotype of flies expressing the G2385R
polymorphic variant, which according to in vitro kinase activity
assessments, behaves like the wild-type protein (West et al.,
2007). Perhaps the G2385R mutation, which resides at the
C-terminal end outside the catalytic core domain of the protein,
promotes LRRK2 deregulation in vivo in an activity-independent
manner. Remarkably, G2385R-expressing flies exposed to rotenone
display marked degeneration in several DA neuronal clusters, in-
cluding PAL, PPM2, and PPL1, that are otherwise unaffected by
normal aging. On the other hand, Y1699C-expressing flies are rela-
tively resistant to the effects of rotenone treatment. Although this
could reflect the utilization of different diseasemechanisms by vari-
ous LRRK2 variants, our previous studies revealed that the extent of
cell death triggered by LRRK2 G2385R expression in response to
stress is comparable with that brought about by the G2019S or
Y1699Cmutant (West et al., 2007). Thus, the mechanism account-
ing for the relative resistance of Y1699C LRRK2-expression toward
rotenone-induced neurodegeneration remains elusive. The differ-
ential sensitivity between G2019S and Y1699C LRRK2 flies to rote-
none does suggest different mechanisms of neuronal degeneration
between the LRRK2 variants. Notably, a number of studies examin-
ing the effectsofY1699CLRRK2expression relative tootherdisease-
associated LRRK2 mutants in other models have also recorded
dissimilaroutcomes. For example,MacLeodet al. (2006) found that,
whereas G2019S LRRK2 expression in primary cortical neurons re-
sults in significant shortening of neurite length and branching, the
phenomenon is not appreciably observed in cortical neurons trans-
fected with Y1699C LRRK2. Notwithstanding this, it appears that
LRRK2 G2385R variant could exert marked neurotoxicity when
over-expressed in Drosophila. Our study thus provides the first in
vivo evidence supporting the association of LRRK2G2385R variant,
otherwise knownas the “AsianAllele,”with an increased risk forPD.
Finally, we demonstrated that parkin coexpression with LRRK2
G2019S mutant in flies affords considerable protection against DA
neurodegenerationduringnormal aging or in response to rotenone.
This is consistent with the widely accepted neuroprotective role of
parkin and also with our previous demonstration that parkin could
mitigate rotenone-mediated toxicity both in vitro and in vivo (Wang
et al., 2005, 2007). Notably, parkin appears to interact with LRRK2
physically (Smith et al., 2005). Whether parkin exerts its protective
effects via its direct association with mutant LRRK2 species and/or
indirectly either by reducing the level of oxidative stress associated
with aging or rotenone exposure, or by promoting mitochondrial
homeostasis, remains to be clarified. Nonetheless, the potential
involvement of mitochondrial dysfunction in LRRK2-induced
degeneration (as implicated by rotenone-treatment studies) is
mechanistically exciting. Already, robust evidence now supports
a functional interaction between parkin and PINK1 in maintain-
ing mitochondrial homeostasis. Furthermore, DJ-1 also appears
to participate directly or indirectly in ensuring propermitochon-
drial function (Andres-Mateos et al., 2007; Thomas and Beal,
2007). A link between parkin and LRRK2 viamitochondria could
potentially help elucidate a common pathway underlying PD
pathogenesis that would be of immense therapeutic relevance.
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